MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Aptevo Therapeutics DPO Ratio 2011-2026 | APVO
Annual DPO Ratio Aptevo Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 239 | 380 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 380 | 239 | 309 |
Quarterly DPO Ratio Aptevo Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 276 | 175 | 269 | - | 218 | 420 | 299 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 420 | 175 | 276 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 19.45 | 1.14 % | $ 909 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Mesoblast Limited
MESO
|
1.25 K | $ 15.44 | 7.82 % | $ 10 B |  Australia |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
72.6 | $ 0.67 | -5.25 % | $ 7.67 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCC
|
1.79 K | - | -5.98 % | $ 34.1 M | USA |
 |
Aytu BioScience
AYTU
|
186 | $ 2.69 | 1.37 % | $ 16.9 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
52.8 | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Merck & Co.
MRK
|
94.5 | $ 117.56 | 1.02 % | $ 294 B | USA |
 |
Moderna
MRNA
|
152 | $ 53.09 | 3.41 % | $ 20.7 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.47 | 3.71 % | $ 856 M | Canada |